Palladium Nanoparticles PdNPs and Breast Cancer

Palladium nanoparticles (PdNPs) have shown potential in the treatment of breast cancer through various mechanisms. Here are some key points regarding their use in breast cancer therapy:

  • PdNPs and Tubastatin A: A study investigated the combined treatment of tubastatin A (TUB-A) and PdNPs against MDA-MB-231 human breast cancer cells. This combination therapy increased apoptosis in human breast cancer cells, providing a targeted therapy for breast cancer without significant side effects.

  • Photothermal Therapy: Trimethyl chitosan (TMC) coated PdNPs have been used as photothermal agents for breast cancer treatment. Upon near-infrared (NIR) laser irradiation, these nanoparticles exhibit good cytotoxic effects in both 2D monolayers and 3D spheroids of MDAMB231 cells, mimicking the tumor microenvironment.

  • Multifunctional Nanoparticle Systems: An efficient multifunctional nanoparticle system was developed for the identification and treatment of triple-negative breast cancer (TNBC). Initially, cetyltrimethylammonium chloride (CTAC) stabilized PdNPs were coated with thiolated chitosan oligosaccharide (thiolated-COS) to enhance their functionality.

  • Drug Delivery: PdNPs can be used in drug delivery systems, such as mesoporous platinum-palladium nanoparticles (PtPd NP), which were synthesized for chemo-photothermal therapy of breast cancer with real-time imaging capabilities.

  • Anticancer Activity: Both platinum and palladium nanoparticles synthesized using Gloriosa superba showed potent anticancer activity against MCF-7 (human breast adenocarcinoma) cells, inducing apoptosis characterized by phosphatidyl serine externalization, membrane disintegration, and blebbing with chromosome condensation.

These studies indicate that PdNPs can be an effective therapeutic agent for breast cancer treatment, offering various advantages such as tunability, desirable photothermal and optical properties, and targeted drug delivery.

References